Xencor, Inc Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs
Xencor, Inc (XNCR) had Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs of $2.13 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts · last filed 2025-02-27
- 2024-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs $2.13M.
- 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs $2.34M; Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs as first filed $2.22M.
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs $2.88M.
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs $3.42M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs | Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs as first filed |
|---|---|---|
| 2024-12-31 | $2.13M 10-K · filed 2025-02-27 | |
| 2023-12-31 | $2.34M 10-K · filed 2025-02-27 | $2.22M 10-K · filed 2024-02-29 |
| 2022-12-31 | $2.88M 10-K/A · filed 2025-02-24 | |
| 2021-12-31 | $3.42M 10-K · filed 2023-02-27 | |
| 2020-12-31 | $4.22M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $3.74M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $3.14M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $2.87M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $3.73M 10-K · filed 2018-02-28 | |
| 2015-12-31 | $3.49M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $3.20M 10-K · filed 2016-03-08 | |
| 2013-12-31 | $2.93M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |